# Safety of KN057 Prophylaxis in Patients With Haemophilia A or B

> **NCT07545395** · PHASE3 · RECRUITING · sponsor: **Suzhou Alphamab Co., Ltd.** · enrollment: 70 (estimated)

## Conditions studied

- Hemophilia A or B

## Interventions

- **DRUG:** KN057

## Key facts

- **NCT ID:** NCT07545395
- **Lead sponsor:** Suzhou Alphamab Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-13
- **Primary completion:** 2027-12-30
- **Final completion:** 2028-03-30
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07545395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07545395, "Safety of KN057 Prophylaxis in Patients With Haemophilia A or B". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07545395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*